HealthFlex
×
  • Home
  • Immunology Book
  • Lab Tests
    • Hematology
    • Fluid analysis
    • CSF
    • Urine Analysis
    • Chemical pathology
    • Blood banking
    • Fungi
    • General pathology
    • Immune system
    • Microbiology
    • Parasitology
    • Pathology
    • Tumor marker
    • Virology
    • Cytology
  • Lectures
    • Bacteriology
    • Immunology
    • Liver
    • Lymph node
    • Lymphoid system
    • Mycology
    • Pathology
    • Virology
  • Blog
    • Economics and technical
    • Fitness health
    • Mental health
    • Nutrition
    • Travel
    • Preventive health
    • Nature and photos
    • General topic
  • Medical Dictionary
  • About Us
  • Contact

Hepatitis B Virus – Part 1 – Hepatitis B Virus, HBV

Hepatitis B Virus – Part 1 – Hepatitis B Virus, HBV
September 19, 2020Lab TestsVirology

Sample

  1. The best sample for the viral hepatitis B markers or profile is serum.
  2. A random sample can be taken.

Purpose of tests (Indications)

  1. Viral hepatitis B marker is done for:
    1. The diagnosis of HBV infection.
    2. The diagnosis of the carrier.
    3. The diagnosis of chronic hepatitis.
    4. Screening of blood for transfusion.

Pathophysiology

  1. HBV is also called serum hepatitis.
  2. Viral hepatitis B is caused by the DNA virus. This is a double-stranded DNA virus and one strand is incomplete.
  3. This virus belongs to the Hepadnaviridae family.
  4. 42 to 47 nm particles are infectious.
    1. 20 nm spherical and 20 nm by 1-micrometer particles are not infectious.
  5. The outcome of the disease is :
    1. Acute hepatitis.
    2. Chronic hepatitis.
    3. Cirrhosis.
    4. Liver cell carcinoma.
  6. This is usually seen in young adults.
  7. Transmitted by:
    1. Blood and blood products.
    2. It can spread by contaminated needles.
    3. It can spread through sexual contact.
    4. It can spread through other body fluids.
    5. There is transplacental spread.
  8. It is Common in (high-risk group):
    1. Multiple Blood transfusion recipients.
    2. Male homosexuals.
    3. Dialysis patients.
    4. Transplant patient.
    5. I/V drug user.
    6. Hospital worker because of needle pricks.
    7. Patient with leukemia and lymphoma.
    8. During delivery can infect the newborn if the mother is a carrier.
    9. A family member with close contact.
  9. Incubation period
    1. This has long incubation varying from 5 weeks to 6 months.
    2. This viral can give acute infection and may develop chronic disease.
  10. Structure of HBV
    1. This is a DNA virus and called a Dane particle.
    2. It has an inner core surrounded by an outer capsule.
    3. The outer capsule contains the antigen called the hepatitis B surface antigen (HBs-Antigen). This is also called as Australia antigen (HBsAg).
    4. The inner core contains HBV core antigen one is called HBc Ag and another antigen is incorporated into the Core antigen is called HBeAg.
    5. The HBcAg is a very small amount so not detectable but its Antibody is found in circulation.
Hepatitis B Virus structure

Hepatitis B Virus structure

  1. There are three antigens:

    1. HBsAg
    2. HBcAg
    3. HBeAg
  2. There are three Antibodies:

    1. Anti-HBsAb
    2. Anti-HBcAb
    3. Anti-HBeAb
  3. Hepatitis B surface antigen (HBsAg)

      1. HBsAg appears first in the blood, so this is a more common test.
      2. HBsAg rises before the appearance of clinical signs and symptoms appear and is detectable.
      3. The peak is during the first week of symptoms.
      4. It returns to a normal level by the time jaundice subsides.
      5. If it persists then the patient will be a carrier or may develop chronic hepatitis.
  4. Hepatitis B surface antibody (HBsAb)

      1. This antibody appears after roughly 4 weeks, after the disappearance of HBsAg.
      2. It indicates the end of the acute phase and the patient complete recovery from the infection.
      3. The patient will develop immunity to HBV infection.
      4. After vaccination, there is the appearance of HBsAb.
  5. Hepatitis Core antigen (HBcAg)

      1. This is not detectable because of the very small quantity and it is incorporated with HBeAg.
  6. Hepatitis B Core Antibody (HBcAb )

      1. This antibody appears after one month of infection.
      2. In acute infection, this will be HBcAb-IgM type and later replaced by HBcAb-IgG type.
      3. This antibody persists in circulation for several years.
      4. This antibody will be present in chronic hepatitis cases.
      5. In the window period when HBsAg is negative and still there are no HBsAb, then this is the antibody present in the patient.
      6. HbcAb-IgM is the marker in the window period in acute infections.
      7. This is also called as the window period marker.
  7. Hepatitis Be antigen (HBeAg)

      1. HBeAg is a marker of the infectivity.
      2. HBeAg appears immediately after the appearance of HBsAg.
      3. HBeAg indicates early and acute disease.
      4. HBeAg positive in chronic hepatitis patients is a sign of a bad prognosis.
      5. The persistence of HBeAg indicates the development of chronic hepatitis.
  8. Hepatitis B e antibody (HBeAb)

    1. The appearance of HBeAb is a sign of recovery.
    2. This antibody shows the end of the acute phase.
Hepatitis B Virus profile

Hepatitis B Virus profile

Clinical presentation

  1. There is variation in the symptoms from mild to severe.
  2. Most of the children and 50% of the adults are asymptomatic.
  3. The symptoms are insidious.
  4. The prodromal period often shows :
    1. Fever.
    2. Malaise.
    3. Myalgia.
  5. The patient may have nausea and vomiting.
  6. There is weight loss.
  7. The acute period with jaundice lasts about one month.
  8. The patient will have jaundice and dark color urine.
  9. <1.5% may develop fulminant hepatitis.
  10. Chronicity decreases with age.
    1. 85% seen in the neonates.
    2. 25 to 50% of children.
    3. 6 to 10% of the adult.
  11. These patients are at high risk for liver cell carcinoma.

Table showing the difference between HAV and HBV:

Presentation HBV HAV
Mode of transmission Parenteral Feco-oral
Incubation period 60 to 160 days 15 to 40 days
Time of spread All the year Fall and winter
Onset Slow Sudden
Chronicity Roughly 5 to 10% Complete recovery
Mortality <0.01% <1%
Prophylaxis γ-globulin protects Some pools of γ-globulin

The significance of various hepatitis markers:

  1. Acute infection
    1. HBsAg positive.
    2. HbcAb- IgM positive.
  2. Chronic infection
    1. 2 to 10 % develop chronic disease.
    2. HBsAg positive.
    3. HbcAb-IgG (Total) is positive.
    4. HBeAg positive indicate highly infective and poor prognosis.
Chronic Hepatitis B Virus profile

Chronic Hepatitis B Virus profile

  1. Recovery stage
    1. HBsAg is negative.
    2. HBsAb is positive.
  2. Window period marker
    1. HBsAg is negative.
    2. HBsAb is negative.
    3. HBcAb-IgM will be positive.
  3. For the HB viral load advice PCR.
    1. PCR qualitative for the HBV genome.
    2. PCR quantitative by HBV DNA by RNA probe.

Table showing various HBV antigens and antibodies

HBV Ag/AB Appears Disappears Significance
HBsAg 4 to 12 weeks 1 to 3 months Acute or chronic infection
HBeAg 1 to 3 weeks 6 to 8 weeks Acute infection
HbcAg not detected
HbSAb 3 to 10 months 6 to 10 years Indicate immunity
HbeAb 4 to 6 weeks 4 to 6 years End of acute infection
HbcAb IgM 2 to 12 weeks 3 to 6 months Acute HBV infection
HbcAb total 3 to 12 weeks Life long Past HBV infection/recovery stage

Table showing various stages of HBV infection:

Test Acute Chronic Recovery Carrier Window period Vaccination
HBsAg positive  positive negative/positive positive negative negative
Anti-IgM HBc positive neg/pos negative negative positive negative
Anti-IgG HBc negative positive positive positive neg/pos positive
HBeAg positive neg/pos negative negative negative negative
Anti-HBeAb negative positive positive positive pos/neg negative
Anti-HBs Ab negative negative positive negative negative positive
PCR positive positive negative negative positive negative

Treatment

  1. In the case of fulminant hepatitis, liver transplantation is needed.
  2. Treatment of chronic HBV infection is indicated when HBV-DNA  >2000 IU/L and serum SGPT is raised.
  3. Antiviral medications are Lamivudine (Epivir), Adefovir (Hepsera), Telbivudine (Tyzeka) and Entecavir (Baraclude).
  4. Interferon alpha-2 is used mainly for young patients.

Prevention

  1. Vaccination is the method of choice.
  2. This should be given at birth to infants born to carrier mothers.

Possible References Used
Go Back to Lab Tests

Comments

Mulazim Hussain Bukhari Reply
February 18, 2020

Excellent

Dr. Riaz Reply
February 20, 2020

Thanks for the comments.

Add Comment Cancel


  • Lab Tests
    • Blood banking
    • Chemical pathology
    • CSF
    • Cytology
    • Fluid analysis
    • Fungi
    • General pathology
    • Hematology
    • Immune system
    • Microbiology
    • Parasitology
    • Pathology
    • Tumor marker
    • Urine Analysis
    • Virology

About Us

Labpedia.net is non-profit health information resource. All informations are useful for doctors, lab technicians, nurses, and paramedical staff. All the tests include details about the sampling, normal values, precautions, pathophysiology, and interpretation.

info@labpedia.net

Quick Links

  • Blog
  • About Us
  • Contact
  • Disclaimer

Our Team

Professor Dr. Riaz Ahmad Bhutta

Dr. Naheed Afroz Syed

Dr. Asad Ahmad, M.D.

Dr. Shehpar Khan, M.D.

Copyright © 2020. All Rights Reserved.
Web development by Farhan Ahmad